Aviragen Therapeutics Announces Inducement Grant for New Employees
September 06 2016 - 6:30PM
Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota
Pharmaceuticals, Inc.), a pharmaceutical company that is developing
the next generation of antivirals, announced today that the Company
has granted two new hires options to purchase an aggregate of
125,000 shares of the Company's common stock with a per share
exercise price of $1.33, the closing price on August 31, 2016. The
stock options have a ten-year term and vests over a period of four
years, with one-fourth vesting on the first anniversary of the
grant date and one-fourth vesting on each of the three succeeding
anniversaries. The option is subject to the terms and conditions of
the Company's 2007 Omnibus Equity and Incentive Plan and the stock
option agreement pursuant to which the option is granted.
The stock option was granted as an inducement
material to the new employees entering into employment with
Aviragen Therapeutics in accordance with NASDAQ Listing Rule
5635(c)(4).
About Aviragen Therapeutics,
Inc.
Aviragen Therapeutics is focused on the discovery
and development of the next generation of direct-acting antivirals
to treat infections that have limited therapeutic options and
affect a significant number of patients globally. The Company has
three product candidates in active clinical development: These
include vapendavir, an oral treatment for human rhinovirus upper
(HRV) respiratory infections in moderate-to-severe asthmatics
currently being evaluated in the Phase 2b SPIRITUS trial; BTA585,
an oral fusion protein inhibitor that has received Fast Track
designation by the U.S. FDA, in Phase 2 development for the
treatment and prevention of respiratory syncytial virus (RSV)
infections; and BTA074, a topical antiviral treatment in Phase 2
development for condyloma caused by human papillomavirus types 6
& 11. For additional information about the Company, please
visit www.aviragentherapeutics.com.
Contacts:
Mark Colonnese
Executive Vice President and Chief Financial Officer
Aviragen Therapeutics, Inc.
(678) 221-3381
mcolonnese@aviragentherapeutics.com
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024